azole resistance – mycolab.ai

Antifungal Efficacy of Ganoderma lucidum and Clotrimazole for Treatment of Denture Stomatitis: A Randomized Clinical Trial

mycolabadmin

This study tested whether Ganoderma lucidum, a medicinal mushroom used in traditional Asian medicine, could treat denture stomatitis as effectively as the standard treatment clotrimazole. Both treatments reduced pain and improved symptoms equally well over two weeks. The results suggest that Ganoderma lucidum could be a useful alternative for patients who don’t respond well to standard antifungal drugs.

The emerging fungal pathogen Cryptococcus gattii: Epidemiology, pathogenesis, immunomodulatory attributes, and drug susceptibility

mycolabadmin

Cryptococcus gattii is a dangerous fungal infection that can affect even healthy people, unlike most fungal infections that target those with weak immune systems. The fungus uses clever tricks to hide from the immune system, including creating protective capsules and producing melanin. Current antifungal drugs like fluconazole are becoming less effective as the fungus develops resistance, making this an urgent public health concern that requires better treatments and early detection.

Ploidy plasticity drives fungal resistance to azoles used in agriculture and clinics

mycolabadmin

Agricultural fungicides called azoles can cause fungi to change their genetic makeup in ways that make them resistant to medical antifungal drugs. Researchers found that when Candida tropicalis (a fungal pathogen) is exposed to tebuconazole, an agricultural fungicide, it can transform into a haploid form (with half the normal chromosomes) that is resistant to both agricultural and clinical azoles. This discovery helps explain why fungal infections are becoming harder to treat in hospitals.

Candida vulturna, the Next Fungal Menace? A Narrative Review

mycolabadmin

Candida vulturna is a newly discovered yeast that causes serious blood infections, particularly in vulnerable patients like premature infants and those with cancer. Though still rare, cases are increasingly appearing in tropical regions with documented hospital outbreaks. While the infection has a better survival rate than related species, it resists several common antifungal drugs, making treatment challenging and requiring careful use of remaining effective medications.

Refractory fungal infection: Three case reports highlighting good practice

mycolabadmin

This case series examines three patients with serious fungal infections that did not respond well to standard antifungal treatments. The cases demonstrate how fungi can develop resistance to common antifungal drugs like azoles, making infections harder to treat. The authors emphasize that accurate identification of the fungus, testing its sensitivity to drugs, monitoring drug levels in the blood, and careful use of antifungal medications are essential for successfully treating these difficult infections.

Detection of ERG11 gene mutation in coding and non-coding regions of clinical Candida glabrata (Nakaseomyces glabratus) isolates from Pakistan

mycolabadmin

Researchers in Pakistan identified genetic mutations in a dangerous fungus called Candida glabrata that makes it resistant to azole drugs, which are commonly used to treat fungal infections. They examined eight clinical samples and found novel mutations in the ERG11 gene, particularly in the promoter region of resistant strains. These findings suggest that the fungus may be developing new ways to survive azole treatment, which has important implications for patient treatment strategies.

Overexpression of efflux pump and biofilm associated genes in itraconazole resistant Candida albicans isolates causing onychomycosis

mycolabadmin

This research examines why some fungal infections of the nails resist treatment with the antifungal drug itraconazole. Scientists found that resistant fungi produce more proteins that pump the drug out of their cells (efflux pumps) and form protective biofilm structures. Understanding these resistance mechanisms could help develop better combination treatments that work alongside antifungal drugs to overcome resistance.

Clinical and Genomic Insights into Antifungal Resistance in Aspergillus Isolates from Thailand

mycolabadmin

Researchers in Thailand identified a dangerous fungal infection caused by Aspergillus fumigatus that is resistant to azole antifungal drugs. This is the first time this specific drug-resistant strain has been found in a patient sample in Thailand, though it had been previously detected in environmental samples. The study used genetic testing to understand how the fungus developed resistance and found that it has altered genes that help it survive the antifungal medications commonly used to treat infections.

Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism of Aspergillus fumigatus

mycolabadmin

Researchers have developed a new type of antifungal drug that uses the fungus’s own enzymes against it. The drug is inactive until it encounters an enzyme produced by Aspergillus fumigatus, where it releases toxic molecules that kill the fungus. Importantly, this approach works against both normal and drug-resistant strains of the fungus, offering hope for treating serious fungal infections that don’t respond to current treatments.

Antifungal susceptibility testing of Microsporum canis isolated from the skin of dermatologically healthy cats

mycolabadmin

Researchers found that about 5% of healthy cats in Chile carry a fungal infection called Microsporum canis that can spread to humans. The concerning discovery is that all strains tested were resistant to fluconazole, a commonly used antifungal medication. The study shows that indoor cats are at higher risk of carrying this fungus and suggests that screening healthy cats could help prevent transmission to people who have close contact with them.

Research Keyword: azole resistance